^
Association details:
| Biomarker: | MSI-H/dMMR + TMB-H + PD-L1 negative |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review
Published date:
08/27/2021
Excerpt:
The 61-year-old male patient was diagnosed with a pancreatic malignancy in our hospital in January 2018... Immune results were PD-L1(-), TMB-H, MMR (p-MMR), MSI (microsatellite stable)...As a result, clinicians had to switch patients to FOLFIRINOX (oxaliplatin, irinotecan, leucovorin and fluorouracil) combined with nivolumab. Fortunately, after eight cycles of chemotherapy combined with immunotherapy, the patient did not progress and the PFS reached 9months...
Secondary therapy:
FOLFIRINOX
DOI:
10.1097/CAD.0000000000001232
